Vindezine (Vindesinum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Antitumor agents of vegetable origin

Included in the formulation
АТХ:

L.01.X   Other antineoplastic agents

Pharmacodynamics:

Pharmacological action - antitumor. It blocks mitotic division of cells in metaphase.

Pharmacokinetics:

Preserves antitumor activity in patients with resistance to combination therapy (including vincristine).

Indications:

Acute lymphocytic leukemia in children (with vincristine resistance), lymphoma (except Hodgkin's disease), chronic granulocytic leukemia (blast crisis), lung cancer (except small cell), breast cancer (with ineffective hormonal therapy), malignant melanoma.

ICD-10

II.C50.C50   Malignant neoplasm of breast

II.C43-C44.C43.9   Malignant melanoma of skin, unspecified

II.C81-C96.C83.9   Diffuse non-Hodgkin's lymphoma, unspecified

II.C81-C96.C83   Diffuse non-Hodgkin's lymphoma

II.C81-C96.C83.7   Tumor of Berkit

II.C81-C96.C92   Myeloid leukemia [myeloid leukemia]

II.C81-C96.C91   Lymphoid leukemia [lymphocytic leukemia]

Contraindications:

Hypersensitivity, severe oppression of bone marrow function (granulocytopenia - less than 1.5 thousand per μL, thrombocytopenia - less than 100 thousand per μL); acute pain in the abdomen (the risk of paralytic intestinal obstruction); acute infectious diseases of a viral, fungal or bacterial nature (including chicken pox, shingles); Charcot-Marie syndrome (demyelinating form).Neuromuscular diseases with simultaneous use of neurotoxic drugs; pregnancy, lactation, radiation therapy of the hepatobiliary region.

Carefully:

Care is required when using drugs with neurotoxicity at the same time. Intra-intrathecal administration is fatal. Enter should be in the largest of the available veins and before inserting make sure that the needle is positioned correctly. Injection is recommended only for personnel with experience of administration. The patient must be warned about the risks associated with treatment. It is necessary to constantly monitor the cardiovascular system, the number of blood cells. With extravasation, the administration is immediately stopped (the rest is injected into another vein), the lesion site is moderately warmed and hyaluronidase is administered. Do not allow eye contact (irritation and ulceration of the cornea) - if this happens, the eye is immediately washed with water (saline solution). Do not mix with other products in the same container.

Pregnancy and lactation:

Contraindicated in breastfeeding and pregnancy.

Dosing and Administration:

Only intravenously, in the form of a bolus injection (directly into the vein) or through a system for infusions with preliminary dilution to a concentration of 1 mg / ml (water for injection, glucose solution or saline solution). Adults - usually 3 mg / m2 body surface, children - 4 mg / m2 with intervals of 7-10 days for 1-3 months (or alternatively, 2 mg / m2 for 2 consecutive days with a break of 5-7 days and repetition of the cycle). The optimal dose is considered to cause mild to moderate leukopenia (avoid persistent leukopenia below 2500 /mm3). The maximum decrease in the number of white blood cells occurs usually 3-5 days after the injection, recovery - after 7 or more days. Adults with a decrease in bone marrow function (due to previous therapy) is recommended to reduce the dose. The maximum total dose is 4 mg / m2.

Side effects:

Anorexia, abdominal pain, nausea, vomiting, constipation, diarrhea, stomatitis, intestinal obstruction, nervous system damage: paresthesia, peripheral neuritis, jaw pain, headache, loss of deep tendon reflexes, general malaise, weakness, depression, convulsions, blindness ; leukopenia (dose-dependent), granulocytopenia,thrombocytopenia, acute dyspnea, bronchospasm; generalized myalgia, pain in the area of ​​the tumor; baldness, skin rashes, chills, fever; reaction at the injection site (irritation, cellulite, phlebitis).

Overdose:

Treatment is symptomatic.

Interaction:

Pharmaceutically incompatible with other medicines. Co-administration with neurotoxic drugs increases the severity of side effects. In combination with mitomycin C against the background of the pathology of the respiratory system, the risk of bronchospasm develops. Reduces the content of phenytoin in the blood, increases convulsive readiness.

Special instructions:

Treatment is carried out in a specialized hospital, in combination with other antitumor drugs drugs. Hematological control (leukocytes, granulocytes, Hb) is necessary before each next injection. With granulocytopenia below 2.5 thousand per μL, it is necessary to postpone the next injection. The maximum decrease in white blood cells occurs in 3-5 days, recovery - after 7-10 days. In case of violations of the liver function, reduce the initial dose. When carrying out intravenous infusion do not allow extravasal solution.Avoid contact with eyes.

Instructions
Up